The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer

Phillip G. Febbo, Philip W. Kantoff, Elizabeth A. Platz, Daniel Casey, Steve Batter, Edward Giovannucci, Charles H. Hennekens, Meir J. Stampfer

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5α-reductase activity are at increased risk for prostate cancer (CAP). A single nucleotide polymorphism of the 5α-reductase type 2 gene (SRDSA2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case- control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95% confidence interval, 0.76-1.20), and leu/leu = 0.84 (95% confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.

Original languageEnglish (US)
Pages (from-to)5878-5881
Number of pages4
JournalCancer Research
Volume59
Issue number23
StatePublished - Dec 1 1999
Externally publishedYes

Fingerprint

Leucine
Glucuronides
Valine
Prostatic Neoplasms
Oxidoreductases
Genes
Genotype
Confidence Intervals
Dihydrotestosterone
Gene Frequency
Codon
Isoenzymes
Single Nucleotide Polymorphism
Testosterone
Odds Ratio
Physicians
Health
Serum
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Febbo, P. G., Kantoff, P. W., Platz, E. A., Casey, D., Batter, S., Giovannucci, E., ... Stampfer, M. J. (1999). The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Research, 59(23), 5878-5881.

The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. / Febbo, Phillip G.; Kantoff, Philip W.; Platz, Elizabeth A.; Casey, Daniel; Batter, Steve; Giovannucci, Edward; Hennekens, Charles H.; Stampfer, Meir J.

In: Cancer Research, Vol. 59, No. 23, 01.12.1999, p. 5878-5881.

Research output: Contribution to journalArticle

Febbo, PG, Kantoff, PW, Platz, EA, Casey, D, Batter, S, Giovannucci, E, Hennekens, CH & Stampfer, MJ 1999, 'The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer', Cancer Research, vol. 59, no. 23, pp. 5878-5881.
Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Research. 1999 Dec 1;59(23):5878-5881.
Febbo, Phillip G. ; Kantoff, Philip W. ; Platz, Elizabeth A. ; Casey, Daniel ; Batter, Steve ; Giovannucci, Edward ; Hennekens, Charles H. ; Stampfer, Meir J. / The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. In: Cancer Research. 1999 ; Vol. 59, No. 23. pp. 5878-5881.
@article{4863d4eb595a44f39e326ebb8d4e287e,
title = "The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer",
abstract = "5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5α-reductase activity are at increased risk for prostate cancer (CAP). A single nucleotide polymorphism of the 5α-reductase type 2 gene (SRDSA2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case- control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95{\%} confidence interval, 0.76-1.20), and leu/leu = 0.84 (95{\%} confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.",
author = "Febbo, {Phillip G.} and Kantoff, {Philip W.} and Platz, {Elizabeth A.} and Daniel Casey and Steve Batter and Edward Giovannucci and Hennekens, {Charles H.} and Stampfer, {Meir J.}",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "59",
pages = "5878--5881",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer

AU - Febbo, Phillip G.

AU - Kantoff, Philip W.

AU - Platz, Elizabeth A.

AU - Casey, Daniel

AU - Batter, Steve

AU - Giovannucci, Edward

AU - Hennekens, Charles H.

AU - Stampfer, Meir J.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - 5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5α-reductase activity are at increased risk for prostate cancer (CAP). A single nucleotide polymorphism of the 5α-reductase type 2 gene (SRDSA2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case- control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95% confidence interval, 0.76-1.20), and leu/leu = 0.84 (95% confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.

AB - 5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5α-reductase activity are at increased risk for prostate cancer (CAP). A single nucleotide polymorphism of the 5α-reductase type 2 gene (SRDSA2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case- control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95% confidence interval, 0.76-1.20), and leu/leu = 0.84 (95% confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.

UR - http://www.scopus.com/inward/record.url?scp=0033233173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033233173&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 5878

EP - 5881

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -